SOUTHERN CALIFORNIA ISLET CELL RESOURCES (SCI-ICR) CENTER

南加州胰岛细胞资源 (SCI-ICR) 中心

• 批准号: 7621996
• 负责人: ARTHUR D RIGGS
• 金额: $ 113.07万
• 依托单位: BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-08-01 至 2008-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7621996
• 关键词: Address; Apoptotic; Area; Bioinformatics; Biological Assay; California; Cell Separation; Cells; Clinical; Clinical assessments; Computer Retrieval of Information on Scientific Projects Database; Databases; Development; Fostering; Funding; Grant; Growth Factor; Institution; Insulin; Islet Cell; Islets of Langerhans; Islets of Langerhans Transplantation; Lead; Multicenter Studies; Organ; Organ Procurements; Outcome; Oxygen; Pathway interactions; Positioning Attribute; Procedures; Protocols documentation; Purpose; Qualifying; Recovery; Research; Research Personnel; Resources; Site; Source; Supplementation; Techniques; Technology; Training; Transplantation; United States National Institutes of Health; Work; base; improved; islet; member; method development; programs; repository; success; technology development

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. DESCRIPTION (provided by applicant): In the previous funding period, the Southern California Islet Cell Resources (SC-ICR) Center has established itself as one of the most productive islet transplantation centers in ICR program while also providing high quality islets to ICR-approved projects nationwide. We have also assembled a consortium of several transplant centers in Southern California and are working to train and qualify them as islet transplantation sites which will use the clinical-grade islets produced by the SC-ICR. In these and other ways, the SC-ICR has demonstrated that it functions as a true islet cell resource center. In the upcoming period we will extend this success to improving islet cell isolation, characterization, and storage. In Specific Aim 1, we plan to expand the capacity of the SC-ICR up to three folds by constructing a fully dedicated facility, adding another islet isolation team, and increasing organ procurement activities. In Specific Aim 2, we are targeting a few crucial areas for improvement in islet recovery and potency. We are investigating oxygen supplementation at specific points in the islet isolation procedure, inhibition of pro-apoptotic pathways, and supplementation of growth factors to maximize the islet yield from every organ. In Specific Aim 3 we establish an extensive platform of islet characterization assays based on latest technologies. These assays focus on providing validated characterization of islet identity and purity, quantitative functional assays for determining islet potency, and establishment of a multicenter study to identify molecules that are associated with clinical outcome. In Specific Aim 4 we address the problem of islet shortage by development methods for islet storage and establishment of a national islet repository. We are also looking beyond cadaveric islet isolation to development of new sources of insulin-producing cells. Finally, we take seriously the purpose of the ICR program to foster cooperation between leading islet isolation centers and have established several collaborative efforts with other members of the ICR program. As part of this effort, we are working to provide access to the many techniques, protocols, databases, and other bioinformatics resources created by the SC-ICR (Specific Aim 5). Thus, the SC-ICR program is positioned to lead advances in islet isolation and distribution activities and the development of technologies for improving islet yield, quality, quality assessment, and clinical utilization.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 描述（由申请人提供）：在上一个资助期内，南加州胰岛细胞资源（SC-ICR）中心已成为ICR项目中最具生产力的胰岛移植中心之一，同时也为全国范围内的ICR批准项目提供高质量的胰岛。我们还在南加州组建了一个由几个移植中心组成的联盟，并正在努力培训他们，使他们成为胰岛移植中心，这些中心将使用SC-ICR生产的临床级胰岛。通过这些和其他方式，《公约》常设委员会证明， 作为真正的胰岛细胞资源中心。 在即将到来的时期，我们将扩大这一成功，以改善胰岛细胞的分离，表征和储存。在具体目标1中，我们计划通过建设一个完全专用的设施，增加另一个胰岛隔离团队，并增加器官采购活动，将SC-ICR的容量扩大三倍。在具体目标2中，我们瞄准了改善胰岛恢复和效力的几个关键领域。我们正在研究在胰岛分离过程中的特定点补充氧气，抑制促凋亡途径，并补充生长因子，以最大限度地提高每个器官的胰岛产量。在具体目标3中，我们建立了一个基于最新技术的广泛的胰岛表征分析平台。这些检测方法侧重于提供经验证的胰岛特性和纯度表征、用于确定胰岛效价的定量功能检测，以及建立多中心研究以鉴定与临床结果相关的分子。在具体目标4中，我们通过开发胰岛储存方法和建立国家胰岛储存库来解决胰岛短缺问题。我们也在寻找从尸体胰岛分离到新的胰岛素生产细胞来源的发展。 最后，我们认真对待ICR计划的目的，以促进领先的胰岛隔离中心之间的合作，并与ICR计划的其他成员建立了几个合作努力。作为这项工作的一部分，我们正在努力提供SC-ICR（具体目标5）创建的许多技术，协议，数据库和其他生物信息学资源。因此，SC-ICR计划的定位是引领胰岛分离和分配活动的进步，以及提高胰岛产量、质量、质量评估和临床利用的技术开发。